Synlogic Inc · OTC:SYBX
Synlogic — Technical Presentation (September 2018)
10 slides from Synlogic's technical presentation, Sep 4, 2018
Slide 1: Discussion of Interim Analysis of Data from Phase 1/2a Clinical Trial of SYNB1618
Discussion of Interim Analysis of Data from Phase 1/2a Clinical Trial of SYNB1618 September 4, 2018 A Novel Class of Living Medicines Synthetic BioticTM medicines to perform and deliver critical therapeutic functions to treat diseases throughout the body
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995, includin
Slide 3: Synthetic Biotic Platform Breadth and Potential: Current Pipeline
Synthetic Biotic Platform Breadth and Potential:Current Pipeline Inborn Errors of MetabolismMetabolic DiseaseImmunomodulation Immuno Oncology 1 Lead Discovery Lead Optimization IND-Enabling Studies Phase I Phase II Hyperammonemia -Urea Cycle Disorder SYNB1020 Phenylketonuria SYNB1618 Organic Acidemi
Slide 4: SYNB1618 for Phenylketonuria (PKU): Goal: Managing Plasma Phe Levels
SYNB1618 for Phenylketonuria (PKU):Goal: Managing Plasma Phe Levels to Enable Increased Intake of Natural Protein PKU is a rare inherited amino acid metabolism disorder Causes build up of amino acid phenylalanine (Phe) in the bodyPhenylalanine is found in all proteinsDiagnosed: 16,500 in US, similar
Slide 5: Mechanism of Action: Designed to Convert Toxic Phenylalanine to Trans-cinnamic Acid
SYNB1618 Mechanism of Action:Designed to Convert Toxic Phenylalanine to Trans-cinnamic Acid Phe PKU Healthy Amino acids fromdietary proteins [Absorption andRecirculation] Phenylalanine Hydroxylase (PAH): converts Phe into Tyrosine Impaired PAH Tyrosine ! Phenylalanine Hippuric acid (HA) Manage Phe l
Slide 6: SYNB1618 in the Clinic: Study Design Phase 1/2a SAD/MAD
5x1010 CFU 7x1010 CFU 1x1010 CFU 1x1011 CFU 5x1011 CFU 5x1010 CFU 1x1010 CFU 1x1011 CFU 2x1011 CFU Timeline Interim Analysis: TCA, HA production in HVs 1x1011 CFU / solid food A randomized, double-blind, placebo-controlled study to assess the safety, tolerability of SYNB1618 in healthy volunteers ac
Slide 7: SYNB1618 in the Clinic: Safety Interim Analysis of Phase 1/2a SAD/MAD Study
SYNB1618 in the Clinic: SafetyInterim Analysis of Phase 1/2a SAD/MAD Study Healthy Volunteer Cohorts The study enrolled 56 healthy volunteers, all of whom received at least one dose of SYNB1618 or placebo. The subjects were predominantly male Caucasians and the age range of enrolled subjects was 18-
Slide 8: Statistically significant dose-dependent activity of SYNB1618 in healthy volunteers
Statistically significant dose-dependent activity of SYNB1618 in healthy volunteers
Slide 9: SYNB1618 in the Clinic: Phase 1/2a SAD/MAD in Healthy Volunteers with Patient Cohort
SYNB1618 in the Clinic:Phase 1/2a SAD/MAD in Healthy Volunteers with Patient Cohort 2017 2018 2019 Q1 Q2 Q3 Q4 Q1 Q2 IND enabling studies SD/MD Patient cohorts SAD / MAD HV Goal: assess safety, tolerability and kinetics in healthy volunteers across a range of dosesIncludes cohorts of SD/MD PKU patie
Slide 10: Synlogic
SyNlOgiC |